AVASTIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Avastin Market Size and Forecast – 2025 to 2032

The Global Avastin Market is estimated to be valued at USD 1,348.8 Mn in 2025 but is expected to decline to USD 812.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -7% from 2025 to 2032. Despite the increasing prevalence of cancer, rising demand for targeted therapies, and Avastin’s use in treating various cancers such as colorectal, lung, breast, and brain cancer, the market is expected to face a decline due to factors like growing competition from biosimilars, pricing pressures, and the availability of alternative therapies. These factors are limiting Avastin's market growth, even as its use continues in the oncology space.

Key Takeaways of the Global Avastin Market

• In 2025, the metastatic colorectal cancer segment is expected to hold the largest market share of 28.1%.
• The vial (100 mg/4 mL) segment is expected to lead with 54.2% of the market share in 2025.
• The online segment is projected to dominate with 55.4% of the market share in 2025.
• North America is expected to lead the market, holding a share of 37.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.3% in 2025.

Market Overview

The trend in the Avastin market is towards the development of more personalized and targeted therapies, as well as the exploration of combination therapies that involve Avastin and other cancer drugs. Additionally, there is a growing focus on the use of biomarkers to identify patients who are most likely to benefit from Avastin treatment, which could help improve patient outcomes and reduce healthcare costs. As the global cancer burden continues to rise, the demand for effective and targeted therapies like Avastin is expected to remain strong in the coming years.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request sample copy

Avastin Market Insights, By Indication - Metastatic colorectal cancer dominates due to the high global prevalence of colorectal cancer

In terms of indication, metastatic colorectal cancer is expected to contribute the highest market share of 28.1% in 2025. Firstly, the increasing prevalence of colorectal cancer worldwide has significantly contributed to the demand for Avastin as a targeted therapy. Colorectal cancer is one of the most common types of cancer, with a high incidence rate globally. The rising number of diagnosed cases has led to a greater need for effective treatment options, such as Avastin, which has shown promising results in improving patient outcomes.

Moreover, Avastin's mechanism of action, which involves inhibiting the growth of blood vessels that supply tumors, has proven to be particularly effective in treating metastatic colorectal cancer. The drug's ability to target the vascular endothelial growth factor (VEGF) pathway has demonstrated significant improvements in progression-free survival and overall survival rates among patients with metastatic colorectal cancer.

In March 2023, as per the National Library of Medicine, Colorectal cancer (CRC) is the third most common cancer globally, responsible for 10% of cancer cases and 9.4% of deaths. Stage IV metastatic CRC has a historically low five-year survival rate of 10-15%, but recent treatments have improved survival to 12-30 months. In the U.S., CRC remains the third most common cancer, with over 106,000 new colon and 44,850 rectal cancer cases in 2022. Survival for stage IV CRC is around 11-14%.

Avastin Market Insights, By Dose Strength - Vial (100 mg/4 mL) segment dominates due to its flexibility and optimal dosing for most patients

In terms of dose strength, the vial (100 mg/4 mL) segment is projected to contribute the highest share of the Avastin market with 54.2% in 2025. This dose strength has been widely adopted by healthcare professionals and patients alike for its convenience, ease of administration, and optimal efficacy.

The 100 mg/4 mL vial of Avastin provides a suitable dose for most patients, allowing for individualized treatment based on body weight and specific indications. This flexibility in dosing has made it a preferred choice among oncologists, as it enables them to tailor the treatment to each patient's unique needs and response to therapy.

Avastin Market Insights, By Sales Channel - Online sales channel dominates due to the increasing adoption of e-commerce platforms and patient preferences for convenience

In terms of sales channel, the online segment is expected to contribute the highest share of the Avastin market with 55.4% in 2025, driven by the increasing adoption of e-commerce platforms and the growing preference for convenience among patients and healthcare providers.

The rise of online pharmacies and specialty drug distributors has revolutionized the way patients access Avastin and other cancer medications. Online sales channels offer a convenient and discreet option for patients to obtain their prescribed treatments without the need for frequent visits to physical pharmacies. This is particularly beneficial for patients who may have mobility issues or live in remote areas with limited access to specialty pharmacies.

Pricing Analysis of Avastin Market

• The pricing of Avastin varies significantly across different countries, reflecting differences in healthcare systems, regulatory policies, and market dynamics. In 2024, the typical out-of-pocket price for Avastin without insurance ranges from approximately USD 1,865.3 to USD 2,056.5 for a 4-milliliter vial. The highest price is seen in the U.S., with an average of USD 1,958.6, while countries such as the U.K. and Italy report lower prices of USD 1,218.4 and USD 650, respectively.
• In contrast, prices in developing countries are much more affordable, with India at USD 575 and South Africa at USD 260. Other European countries like Spain, Portugal, and Switzerland exhibit varying prices, with Spain offering the lowest at USD 358.8. The differences in Avastin pricing are influenced by factors such as national healthcare policies, government subsidies, and the availability of alternative treatment options like biosimilars. These pricing variations highlight the ongoing challenges in providing equitable access to life-saving cancer treatments across regions.

Regional Insights

To learn more about this report, Request sample copy

North America Avastin Market Analysis and Trends

North America dominates the global Avastin market with an estimated share of 37.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, coupled with a high adoption rate of advanced medical treatments. The presence of major pharmaceutical companies, such as Genentech (a subsidiary of Roche), which develops and manufactures Avastin, further solidifies the region's position. Additionally, favorable reimbursement policies and a strong emphasis on cancer research and treatment contribute to the market's growth. The U.S., in particular, plays a significant role in driving the demand for Avastin, given its large patient population and substantial healthcare expenditure.

Asia Pacific Avastin Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the global Avastin market with a share of 25.3% in 2025. This growth can be ascribed to several factors, including the rising prevalence of cancer, increasing healthcare awareness, and growing disposable incomes. Countries such as China, Japan, and India are witnessing a surge in demand for advanced cancer therapies, including Avastin.

Governments in the region are implementing supportive policies and initiatives to improve healthcare access and affordability. The expanding middle class and the development of healthcare infrastructure in emerging economies further contribute to the market's rapid growth. Collaborative efforts between international pharmaceutical companies and local players are also driving the adoption of Avastin in the Asia Pacific region.

Global Avastin Market Outlook for Key Countries

U.S. Avastin Market Trends

The U.S. market for Avastin is highly developed and mature. The country's advanced healthcare system, extensive research and development activities, and a strong focus on personalized medicine contribute to the widespread use of Avastin. Key players such as Genentech have a significant presence in the U.S., driving innovation and market growth. The market is supported by favorable reimbursement policies and a high demand for targeted cancer therapies.

For example, Genentech (Part of Roche) offers financial assistance programs to help patients afford Avastin, including options for those with or without insurance. The Genentech Oncology Co-pay Assistance Program helps patients with insurance but needing additional cost support.

China Avastin Market Trends

China's market for Avastin is experiencing rapid growth due to the increasing cancer burden and the government's efforts to improve healthcare access. The country's large population, coupled with rising healthcare awareness and disposable incomes, is driving the demand for advanced cancer treatments. Local pharmaceutical companies are collaborating with international players to develop and manufacture biosimilars of Avastin, further expanding the market's potential.

For instance, in May 2025, Harbin, the capital of Heilongjiang Province of China, launched a three-year project offering free screenings for digestive system tumors to 2.4 million people. Using a more effective stool DNA test, the initiative identifies high-risk individuals earlier than traditional tests. Colorectal cancer, a major concern in China, has a high survival rate when detected early, with a five-year survival rate of over 90%.

Japan Avastin Market Trends

Japan continues to be a significant market for Avastin, given its advanced healthcare system and a high prevalence of cancer. The country's aging population and a strong focus on innovative cancer therapies contribute to the market's growth. Japanese pharmaceutical companies, such as Chugai Pharmaceutical (a subsidiary of Roche), play a crucial role in the development and distribution of Avastin in the country.

For example, according to Springer Nature Limited, Japan is pioneering Boron Neutron Capture Therapy (BNCT), a targeted cancer treatment approved in 2020 for advanced or recurrent head and neck tumors. BNCT uses precise radiation that minimizes damage to healthy tissue by targeting tumors with boron and neutrons. It is now being used for more difficult cases, with over 500 patients treated so far, and other countries are following Japan's lead in developing similar facilities.

Germany Avastin Market Trends

Germany's market for Avastin is characterized by a well-established healthcare infrastructure and a strong emphasis on precision medicine. The country's robust research and development ecosystem, coupled with favorable reimbursement policies, supports the adoption of targeted cancer therapies. Key players in the German Avastin market focus on collaborations and partnerships to drive innovation and expand patient access to Avastin.

For example, Germany's "Molecularly Targeted Therapy" (MTT) program focuses on developing targeted cancer treatments through preclinical research and patient insights. It explores combination therapies for pediatric and hematologic cancers, targeting tumor-host interactions and genetic factors. The program bridges discovery and clinical application, supporting precision oncology and the development of effective treatment strategies for clinical trials.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments

• In April 2023, Roche, one of the global leaders in oncology, announced that its combination therapy of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly reduced the risk of cancer recurrence in patients with hepatocellular carcinoma (HCC) following curative surgery or ablation. The findings from the Phase III IMbrave050 trial mark the first-ever positive results in the adjuvant HCC setting and were presented at the AACR Annual Meeting 2023.

Market Report Scope

Avastin Market Report Coverage

Avastin Market Dynamics

To learn more about this report, Request sample copy

Avastin Market Driver - Increasing Prevalence of Cancer

The global Avastin market, despite the increasing prevalence of cancer worldwide, is experiencing steady growth. Although the rising number of cancer cases, including colorectal, lung, breast, and ovarian cancers, contribute to a higher demand for treatments, the market is not experiencing significant growth. Avastin, a monoclonal antibody that inhibits tumor blood vessel growth, remains a valuable treatment option, but its market is being constrained by factors such as increasing competition from biosimilars, pricing pressures, and the availability of alternative therapies. As a result, while the burden of cancer increases, these challenges are limiting Avastin's market growth in the coming years.

For instance, according to data by the WHO, in February 2025, cancer remains a leading global health issue, accounting for nearly 10 million deaths worldwide in 2020, or about one in six deaths. The most common types of cancer in 2020 included breast, lung, colon and rectum, prostate, skin (non-melanoma), and stomach cancers. Lung cancer was the most lethal, followed by colon/rectum, liver, stomach, and breast cancers. Approximately 400,000 children are diagnosed with cancer each year, and while the types of cancer vary by country, cervical cancer is notably the most common in 23 nations.

Avastin Market Opportunity - Advancements in Biotechnology for Market

The Global Avastin Market is poised to benefit from the rapid advancements in biotechnology, presenting a significant opportunity for growth and innovation. The field of biotechnology has witnessed remarkable progress in recent years, with cutting-edge techniques and technologies emerging to enhance the development, production, and delivery of biologic drugs like Avastin. These advancements have the potential to streamline the manufacturing process, improve the efficacy and safety profile of the drug, and expand its therapeutic applications. For instance, the integration of genetic engineering and recombinant DNA technology can enable the creation of novel Avastin variants with enhanced targeting capabilities and reduced immunogenicity.

Additionally, the advent of precision medicine and biomarker-driven approaches can help identify patient subgroups most likely to respond positively to Avastin treatment, thereby optimizing its use and improving patient outcomes. For example, Genentech, has been at the forefront of integrating cutting-edge biotechnology to enhance the development of biologic drugs. The company uses advanced recombinant DNA technology and genetic engineering to produce Avastin, which is one of the first monoclonal antibodies approved for cancer treatment.

Analyst Opinion (Expert Opinion)

• The global Avastin market is undergoing a significant transformation, with a projected decline by 2032. This shift is primarily attributed to the increasing competition from biosimilars, which offer cost-effective alternatives to the original biologic.
• Emerging opportunities within the biosimilar sector are notable, particularly in regions like North America and Asia Pacific, where healthcare systems are increasingly adopting biosimilars to reduce treatment costs. However, challenges persist, including physician hesitancy and regulatory hurdles related to interchangeability and biosimilarity testing. Conferences, such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), have been instrumental in advancing research on biosimilars, influencing policy and technological advancements in oncology. For instance, the ASCO 2025 conference highlighted that a bevacizumab biosimilar demonstrated similar efficacy in delaying cancer progression in metastatic colorectal cancer patients, supporting its inclusion in treatment guidelines. These developments underscore the evolving dynamics of the Avastin market, with biosimilars poised to play a pivotal role in shaping the future of cancer therapy.

Market Segmentation

•  Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Metastatic colorectal cancer
  • Non-squamous non-small cell lung cancer
  • Recurrent glioblastoma
  • Metastatic renal cell carcinoma
  • Persistent cervical cancer
  • Recurrent cervical cancer
  • Metastatic cervical cancer
  • Stage III or IV epithelial ovarian cancer
  • Stage III or IV fallopian tube cancer
  • Stage III or IV primary peritoneal cancer
  • Platinum-resistant recurrent epithelial ovarian cancer
  • Platinum-resistant recurrent fallopian tube cancer
  • Platinum-resistant recurrent primary peritoneal cancer
  • Platinum-sensitive recurrent epithelial ovarian cancer
  • Platinum-sensitive recurrent fallopian tube cancer
  • Platinum-sensitive recurrent primary peritoneal cancer
  • Hepatocellular carcinoma
•  Dose Strength Insights (Revenue, USD Mn, 2020 - 2032)
  • Vial (100 mg/4 mL)
  • Vial (400 mg/16 mL)
•  Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Genentech (Part of Roche)

Sources

Primary Research Interviews

• Oncologists and Cancer Care Specialists
• Clinical Researchers and Medical Professionals
• Hospital Administrators
• Regulatory Authorities
• Pharmacists and Pharmacovigilance Experts

Databases

• World Health Organization (WHO)
• National Cancer Institute (NCI)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Chinese Food and Drug Administration (CFDA)
• Indian Council of Medical Research (ICMR)
• Global Health Data Exchange (GHDx)

Magazines

• The Oncology Journal
• The Cancer Letter
• Cancer Research Journal
• The Journal of Clinical Oncology

Journals

• Nature Reviews Cancer
• The Lancet Oncology
• Journal of Clinical Oncology
• Cancer Cell
• European Journal of Cancer

Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Reuters Health
• Bloomberg Health

Associations

• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• National Comprehensive Cancer Network (NCCN)
• American Association for Cancer Research (AACR)
• International Agency for Research on Cancer (IARC)

Public Domain Sources

• WHO International Agency for Research on Cancer (IARC) Reports
• The National Institute for Health and Care Excellence (NICE)
• U.S. National Library of Medicine

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years